<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38378550</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus.</ArticleTitle><Pagination><StartPage>75</StartPage><MedlinePgn>75</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">75</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-023-02097-8</ELocationID><Abstract><AbstractText>Early since the onset of the COVID-19 pandemic, the medical and scientific community were aware of extra respiratory actions of SARS-CoV-2 infection. Endothelitis, hypercoagulation, and hypofibrinolysis were identified in COVID-19 patients as subsequent responses of endothelial dysfunction. Activation of the endothelial barrier may increase the severity of the disease and contribute to long-COVID syndrome and post-COVID sequelae. Besides, it may cause alterations in primary, secondary, and tertiary hemostasis. Importantly, these responses have been highly decisive in the evolution of infected patients also diagnosed with diabetes mellitus (DM), who showed previous endothelial dysfunction. In this review, we provide an overview of the potential triggers of endothelial activation related to COVID-19 and COVID-19 under diabetic milieu. Several mechanisms are induced by both the viral particle itself and by the subsequent immune-defensive response (i.e., NF-&#x3ba;B/NLRP3 inflammasome pathway, vasoactive peptides, cytokine storm, NETosis, activation of the complement system). Alterations in coagulation mediators such as factor VIII, fibrin, tissue factor, the von Willebrand factor: ADAMST-13 ratio, and the kallikrein-kinin or plasminogen-plasmin systems have been reported. Moreover, an imbalance of thrombotic and thrombolytic (tPA, PAI-I, fibrinogen) factors favors hypercoagulation and hypofibrinolysis. In the context of DM, these mechanisms can be exacerbated leading to higher loss of hemostasis. However, a series of therapeutic strategies targeting the activated endothelium such as specific antibodies or inhibitors against thrombin, key cytokines, factor X, complement system, the kallikrein-kinin system or NETosis, might represent new opportunities to address this hypercoagulable state present in COVID-19 and DM. Antidiabetics may also ameliorate endothelial dysfunction, inflammation, and platelet aggregation. By improving the microvascular pathology in COVID-19 and post-COVID subjects, the associated comorbidities and the risk of mortality could be reduced.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valencia</LastName><ForeName>In&#xe9;s</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Molecular Neuroinflammation and Neuronal Plasticity Research Laboratory, Hospital Universitario Santa Cristina, IIS Hospital Universitario de La Princesa, 28009, Madrid, Spain. valenciafernandezines@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumpuy-Castillo</LastName><ForeName>Jairo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Diabetes and Vascular Pathology, IIS-Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, 28040, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Biomedical Research Centre On Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magalhaes</LastName><ForeName>Giselle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, 28029, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Ferrer</LastName><ForeName>Carlos F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, 28029, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Pharmacology and Metabolism (FARMAVASM), IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenzo</LastName><ForeName>&#xd3;scar</ForeName><Initials>&#xd3;</Initials><AffiliationInfo><Affiliation>Laboratory of Diabetes and Vascular Pathology, IIS-Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, 28040, Madrid, Spain. oscar.lorenzo@uam.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Biomedical Research Centre On Diabetes and Associated Metabolic Disorders (CIBERDEM) Network, Madrid, Spain. oscar.lorenzo@uam.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peir&#xf3;</LastName><ForeName>Concepci&#xf3;n</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medicine, Universidad Aut&#xf3;noma de Madrid, 28029, Madrid, Spain. concha.peiro@uam.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vascular Pharmacology and Metabolism (FARMAVASM), IdiPAZ, Madrid, Spain. concha.peiro@uam.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CD22/00101</GrantID><Agency>Instituto de Salud Carlos III</Agency><Country/></Grant><Grant><GrantID>FPI-UAM</GrantID><Agency>Universidad Aut&#xf3;noma de Madrid</Agency><Country/></Grant><Grant><GrantID>Maria Zambrano postdoctoral grant</GrantID><Agency>European Union-Next Generation EU</Agency><Country/></Grant><Grant><GrantID>SAF2017-84776-R</GrantID><Agency>Ministerio de Econom&#xed;a y Competitividad</Agency><Country/></Grant><Grant><GrantID>P120/00923</GrantID><Agency>Instituto de Salud Carlos III and Fondo de Investigaciones Sanitarias</Agency><Country/></Grant><Grant><GrantID>SPACE2-CV-COVID-CM</GrantID><Agency>REACT-EU-Comunidad de Madrid and the European Regional Development Fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="Y">Thrombophilia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="Y">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004727" MajorTopicYN="N">Endothelium</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coagulation</Keyword><Keyword MajorTopicYN="N">Diabetes mellitus</Keyword><Keyword MajorTopicYN="N">Endothelial cells</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Thrombosis</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>22</Day><Hour>12</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>21</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>20</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38378550</ArticleId><ArticleId IdType="pmc">PMC10880237</ArticleId><ArticleId IdType="doi">10.1186/s12933-023-02097-8</ArticleId><ArticleId IdType="pii">10.1186/s12933-023-02097-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med. 2011;364(18):1746&#x2013;1760. doi: 10.1056/NEJMra1011670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1011670</ArticleId><ArticleId IdType="pubmed">21542745</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2019;16(3):166&#x2013;179. doi: 10.1038/s41569-018-0110-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-018-0110-0</ArticleId><ArticleId IdType="pubmed">30429532</ArticleId></ArticleIdList></Reference><Reference><Citation>Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738&#x2013;1742. doi: 10.1111/jth.14850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14850</ArticleId><ArticleId IdType="pmc">PMC9906150</ArticleId><ArticleId IdType="pubmed">32302438</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt FA, Havervall S, Adelmeijer J, Lundstr&#xf6;m A, Rudberg A, Magnusson M, et al. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Res Pract Thromb Haemost. 2021;5(1):132&#x2013;141. doi: 10.1002/rth2.12462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12462</ArticleId><ArticleId IdType="pmc">PMC7845083</ArticleId><ArticleId IdType="pubmed">33537537</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421&#x2013;1424. doi: 10.1111/jth.14830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14830</ArticleId><ArticleId IdType="pmc">PMC7262324</ArticleId><ArticleId IdType="pubmed">32271988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren B, Yan F, Deng Z, Zhang S, Xiao L, Wu M, et al. Extremely high incidence of lower extremity deep venous thrombosis in 48 Patients with severe COVID-19 in Wuhan. Circulation. 2020;142(2):181&#x2013;183. doi: 10.1161/CIRCULATIONAHA.120.047407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047407</ArticleId><ArticleId IdType="pubmed">32412320</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou AG, Vrettou CS, Keskinidou C, Dimopoulou I, Kotanidou A, Orfanos SE. Endotheliopathy in Acute COVID-19 and Long COVID. Int J Mol Sci. 2023;24(9):8237. doi: 10.3390/ijms24098237.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24098237</ArticleId><ArticleId IdType="pmc">PMC10179170</ArticleId><ArticleId IdType="pubmed">37175942</ArticleId></ArticleIdList></Reference><Reference><Citation>Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46&#x2013;e47. doi: 10.1016/S2213-2600(20)30216-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30216-2</ArticleId><ArticleId IdType="pmc">PMC7185942</ArticleId><ArticleId IdType="pubmed">32353251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kole C, Stefanou &#x395;, Karvelas N, Schizas D, Toutouzas KP. Acute and post-acute COVID-19 cardiovascular complications: a comprehensive review. Cardiovasc Drugs Ther. 2023 doi: 10.1007/s10557-023-07465-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-023-07465-w</ArticleId><ArticleId IdType="pmc">PMC10199303</ArticleId><ArticleId IdType="pubmed">37209261</ArticleId></ArticleIdList></Reference><Reference><Citation>Saluja P, Gautam N, Yadala S, Venkata AN. Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: a systematic review of reported cases. Thromb Res. 2022;214:115&#x2013;121. doi: 10.1016/j.thromres.2022.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.04.020</ArticleId><ArticleId IdType="pmc">PMC9060716</ArticleId><ArticleId IdType="pubmed">35533526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, et al. Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023;11(3):e807. doi: 10.1002/iid3.807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.807</ArticleId><ArticleId IdType="pmc">PMC10022421</ArticleId><ArticleId IdType="pubmed">36988252</ArticleId></ArticleIdList></Reference><Reference><Citation>Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7(10):803&#x2013;815. doi: 10.1038/nri2171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2171</ArticleId><ArticleId IdType="pubmed">17893694</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassar M, Daoud A, Nso N, Medina L, Ghernautan V, Bhangoo H, et al. Diabetes mellitus and COVID-19: review article. Diabetes Metab Syndr. 2021;15(6):102268. doi: 10.1016/j.dsx.2021.102268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102268</ArticleId><ArticleId IdType="pmc">PMC8416292</ArticleId><ArticleId IdType="pubmed">34562865</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G, Pine AB, Meizlish ML, Chang C, Zhang H, Bahel P, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575&#x2013;e582. doi: 10.1016/S2352-3026(20)30216-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30216-7</ArticleId><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang N, Wang C, Zhu F, Mao H, Bai P, Chen L, et al. Risk factors for poor outcomes of diabetes patients with COVID-19: a single-center, retrospective study in early outbreak in China. Front Endocrinol. 2020;11:571037. doi: 10.3389/fendo.2020.571037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.571037</ArticleId><ArticleId IdType="pmc">PMC7543084</ArticleId><ArticleId IdType="pubmed">33071977</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt N, Noval MG, Kaur R, Amadori L, Gildea M, Sajja S, et al. SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels. Nat Cardiovasc Res. 2023;2(10):899&#x2013;916. 10.1038/s44161-023-00336-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10702930</ArticleId><ArticleId IdType="pubmed">38076343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salazar B, Holwerda M, St&#xfc;dle C, Piragyte I, Mercader N, Engelhardt B, et al. COVID-19 and the vasculature: current aspects and long-term consequences. Front Cell Dev Biol. 2022;10:824851. doi: 10.3389/fcell.2022.824851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.824851</ArticleId><ArticleId IdType="pmc">PMC8887620</ArticleId><ArticleId IdType="pubmed">35242762</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73(3):924&#x2013;967. doi: 10.1124/pharmrev.120.000096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pharmrev.120.000096</ArticleId><ArticleId IdType="pubmed">34088867</ArticleId></ArticleIdList></Reference><Reference><Citation>Birnhuber A, Flie&#xdf;er E, Gorkiewicz G, Zacharias M, Seeliger B, David S, et al. Between inflammation and thrombosis: endothelial cells in COVID-19. Eur Respir J. 2021;58(3):2100377. doi: 10.1183/13993003.00377-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00377-2021</ArticleId><ArticleId IdType="pmc">PMC8112008</ArticleId><ArticleId IdType="pubmed">33958433</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ardes D, Boccatonda A, Cocco G, Fabiani S, Rossi I, Bucci M, et al. Impaired coagulation, liver dysfunction and COVID-19: discovering an intriguing relationship. World J Gastroenterol. 2022;28(11):1102&#x2013;1112. doi: 10.3748/wjg.v28.i11.1102.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v28.i11.1102</ArticleId><ArticleId IdType="pmc">PMC8985482</ArticleId><ArticleId IdType="pubmed">35431501</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Agnillo F, Walters K, Xiao Y, Sheng Z, Scherler K, Park J, et al. Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19. Sci Transl Med. 2021;13(620):7790. doi: 10.1126/scitranslmed.abj7790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj7790</ArticleId><ArticleId IdType="pmc">PMC11000440</ArticleId><ArticleId IdType="pubmed">34648357</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt BJ, Jurd KM. Endothelial cell activation. BMJ. 1998;316(7141):1328&#x2013;1329. doi: 10.1136/bmj.316.7141.1328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.316.7141.1328</ArticleId><ArticleId IdType="pmc">PMC1113063</ArticleId><ArticleId IdType="pubmed">9563977</ArticleId></ArticleIdList></Reference><Reference><Citation>Watany MM, Abdou S, Elkolaly R, Elgharbawy N, Hodeib H. Evaluation of admission levels of P, E and L selectins as predictors for thrombosis in hospitalized COVID-19 patients. Clin Exp Med. 2022;22(4):567&#x2013;575. doi: 10.1007/s10238-021-00787-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-021-00787-9</ArticleId><ArticleId IdType="pmc">PMC8778493</ArticleId><ArticleId IdType="pubmed">35061142</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian Sorbeni F, et al. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J. 2022;19(1):92. doi: 10.1186/s12985-022-01814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250&#x2013;256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473&#x2013;474. doi: 10.1126/science.abb8925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8925</ArticleId><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Low RN, Low RJ, Akrami A. A review of cytokine-based pathophysiology of Long COVID symptoms. Front Med. 2023;10:1011936. doi: 10.3389/fmed.2023.1011936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1011936</ArticleId><ArticleId IdType="pmc">PMC10103649</ArticleId><ArticleId IdType="pubmed">37064029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21(1):190. doi: 10.1186/s12933-022-01623-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01623-4</ArticleId><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167&#x2013;173. doi: 10.1016/j.cca.2020.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.04.027</ArticleId><ArticleId IdType="pmc">PMC7195008</ArticleId><ArticleId IdType="pubmed">32348783</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P, Caraffa A, Gallenga CE, Ross R, Kritas SK, Frydas I, et al. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra) J Biol Regul Homeost Agents. 2020;34(5):1623&#x2013;1627. doi: 10.23812/20-34-4EDIT-65.</Citation><ArticleIdList><ArticleId IdType="doi">10.23812/20-34-4EDIT-65</ArticleId><ArticleId IdType="pubmed">32744052</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter RM, Young MK, Petri WAO, Lyons GR, Gilchrist C, Carey RM, et al. Repressed Ang 1&#x2013;7 in COVID-19 Is inversely associated with inflammation and coagulation. mSphere. 2022;7(4):e0022022. doi: 10.1128/msphere.00220-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msphere.00220-22</ArticleId><ArticleId IdType="pmc">PMC9429950</ArticleId><ArticleId IdType="pubmed">35913134</ArticleId></ArticleIdList></Reference><Reference><Citation>Peir&#xf3; C, Moncada S. Substituting angiotensin-(1&#x2013;7) to prevent lung damage in SARS-CoV-2 infection? Circulation. 2020;141(21):1665&#x2013;1666. doi: 10.1161/CIRCULATIONAHA.120.047297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047297</ArticleId><ArticleId IdType="pmc">PMC7243666</ArticleId><ArticleId IdType="pubmed">32242749</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin G, Liu S, Yang L, Yu W, Zhang Y. Myeloid cells in COVID-19 microenvironment. Signal Transduct Target Ther. 2021;6(1):372. doi: 10.1038/s41392-021-00792-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00792-0</ArticleId><ArticleId IdType="pmc">PMC8549428</ArticleId><ArticleId IdType="pubmed">34707085</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobjeva NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry. 2020;85(10):1178&#x2013;1190. doi: 10.1134/S0006297920100065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297920100065</ArticleId><ArticleId IdType="pmc">PMC7590568</ArticleId><ArticleId IdType="pubmed">33202203</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiam HR, Wong SL, Wagner DD, Waterman CM. Cellular mechanisms of NETosis. Annu Rev Cell Dev Biol. 2020;36:191&#x2013;218. doi: 10.1146/annurev-cellbio-020520-111016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-020520-111016</ArticleId><ArticleId IdType="pmc">PMC8499668</ArticleId><ArticleId IdType="pubmed">32663035</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532&#x2013;1535. doi: 10.1126/science.1092385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1092385</ArticleId><ArticleId IdType="pubmed">15001782</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 2010;107(36):15880&#x2013;15885. doi: 10.1073/pnas.1005743107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1005743107</ArticleId><ArticleId IdType="pmc">PMC2936604</ArticleId><ArticleId IdType="pubmed">20798043</ArticleId></ArticleIdList></Reference><Reference><Citation>Folco EJ, Mawson TL, Vromman A, Bernardes-Souza B, Franck G, Persson O, et al. Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1&#x3b1; and cathepsin G. Arterioscler Thromb Vasc Biol. 2018;38(8):1901&#x2013;1912. doi: 10.1161/ATVBAHA.118.311150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.118.311150</ArticleId><ArticleId IdType="pmc">PMC6202190</ArticleId><ArticleId IdType="pubmed">29976772</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. doi: 10.1084/jem.20200652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200652</ArticleId><ArticleId IdType="pmc">PMC7161085</ArticleId><ArticleId IdType="pubmed">32302401</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, Liu J, Yan N. Endothelial dysfunction induced by extracellular neutrophil traps plays important role in the occurrence and treatment of extracellular neutrophil traps-related disease. Int J Mol Sci. 2022;23(10):5626. doi: 10.3390/ijms23105626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23105626</ArticleId><ArticleId IdType="pmc">PMC9147606</ArticleId><ArticleId IdType="pubmed">35628437</ArticleId></ArticleIdList></Reference><Reference><Citation>Moschonas IC, Tselepis AD. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis. 2019;288:9&#x2013;16. doi: 10.1016/j.atherosclerosis.2019.06.919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2019.06.919</ArticleId><ArticleId IdType="pubmed">31280097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Yalavarthi S, Shi H, Gockman K, Zuo M, Madison JA, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5(11):e138999. doi: 10.1172/jci.insight.138999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.138999</ArticleId><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Walport MJ. Complement first of two parts. N Engl J Med. 2001;344(14):1058&#x2013;1066. doi: 10.1056/NEJM200104053441406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200104053441406</ArticleId><ArticleId IdType="pubmed">11287977</ArticleId></ArticleIdList></Reference><Reference><Citation>Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, et al. Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol. 2020;146(1):215&#x2013;217. doi: 10.1016/j.jaci.2020.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.006</ArticleId><ArticleId IdType="pmc">PMC7224678</ArticleId><ArticleId IdType="pubmed">32417135</ArticleId></ArticleIdList></Reference><Reference><Citation>Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020;130(11):6151&#x2013;6157. doi: 10.1172/JCI141374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141374</ArticleId><ArticleId IdType="pmc">PMC7598040</ArticleId><ArticleId IdType="pubmed">32759504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L, Sahu SK, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol. 2021;6(59):abh2259. doi: 10.1126/sciimmunol.abh2259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abh2259</ArticleId><ArticleId IdType="pmc">PMC8158979</ArticleId><ArticleId IdType="pubmed">34446527</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinkovits G, Mez&#x151; B, R&#xe9;ti M, M&#xfc;ller V, Iv&#xe1;nyi Z, G&#xe1;l J, et al. Complement overactivation and consumption predicts in-hospital mortality in SARS-CoV-2 infection. Front Immunol. 2021;12:663187. doi: 10.3389/fimmu.2021.663187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.663187</ArticleId><ArticleId IdType="pmc">PMC8027327</ArticleId><ArticleId IdType="pubmed">33841446</ArticleId></ArticleIdList></Reference><Reference><Citation>Propson NE, Roy ER, Litvinchuk A, K&#xf6;hl J, Zheng H. Endothelial C3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J Clin Invest. 2021;131(1):e140966. doi: 10.1172/JCI140966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140966</ArticleId><ArticleId IdType="pmc">PMC7773352</ArticleId><ArticleId IdType="pubmed">32990682</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht EA, Chinnaiyan AM, Varambally S, Kumar-Sinha C, Barrette TR, Sarma JV, et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol. 2004;164(3):849&#x2013;859. doi: 10.1016/S0002-9440(10)63173-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63173-2</ArticleId><ArticleId IdType="pmc">PMC1613300</ArticleId><ArticleId IdType="pubmed">14982839</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischetti F, Tedesco F. Cross-talk between the complement system and endothelial cells in physiologic conditions and in vascular diseases. Autoimmunity. 2006;39(5):417&#x2013;428. doi: 10.1080/08916930600739712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930600739712</ArticleId><ArticleId IdType="pubmed">16923542</ArticleId></ArticleIdList></Reference><Reference><Citation>Otifi HM, Adiga BK. Endothelial dysfunction in Covid-19 infection. Am J Med Sci. 2022;363(4):281&#x2013;287. doi: 10.1016/j.amjms.2021.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2021.12.010</ArticleId><ArticleId IdType="pmc">PMC8802031</ArticleId><ArticleId IdType="pubmed">35093394</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhargavan B, Kanmogne GD. SARS-CoV-2 spike proteins and cell-cell communication inhibits TFPI and induces thrombogenic factors in human lung microvascular endothelial cells and neutrophils: implications for COVID-19 coagulopathy pathogenesis. Int J Mol Sci. 2022;23(18):10436. doi: 10.3390/ijms231810436.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231810436</ArticleId><ArticleId IdType="pmc">PMC9499475</ArticleId><ArticleId IdType="pubmed">36142345</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Benigni A, Remuzzi G. SARS-CoV-2 and the spike protein in endotheliopathy. Trends Microbiol. 2023 doi: 10.1016/j.tim.2023.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2023.06.004</ArticleId><ArticleId IdType="pmc">PMC10258582</ArticleId><ArticleId IdType="pubmed">37393180</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteil V, Kwon H, Prado P, Hagelkr&#xfc;ys A, Wimmer RA, Stahl M, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905&#x2013;913.e7. doi: 10.1016/j.cell.2020.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.004</ArticleId><ArticleId IdType="pmc">PMC7181998</ArticleId><ArticleId IdType="pubmed">32333836</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotoli BM, Barilli A, Visigalli R, Ferrari F, Dall'Asta V. Endothelial cell activation by SARS-CoV-2 spike S1 protein: a crosstalk between endothelium and innate immune cells. Biomedicines. 2021;9(9):1220. doi: 10.3390/biomedicines9091220.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9091220</ArticleId><ArticleId IdType="pmc">PMC8470710</ArticleId><ArticleId IdType="pubmed">34572407</ArticleId></ArticleIdList></Reference><Reference><Citation>Villacampa A, Alfaro E, Morales C, D&#xed;az-Garc&#xed;a E, L&#xf3;pez-Fern&#xe1;ndez C, Bartha JL, et al. SARS-CoV-2 protein activates NLRP3 inflammasome and deregulates coagulation factor in endothelial and immune cells. Cell Commun Signal. 2023 doi: 10.1186/s12964-023-01397-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-023-01397-6</ArticleId><ArticleId IdType="pmc">PMC10788971</ArticleId><ArticleId IdType="pubmed">38225643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J, Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J Clin Invest. 2022;132(15):e161167. doi: 10.1172/JCI161167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI161167</ArticleId><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5(1):293. doi: 10.1038/s41392-020-00454-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00454-7</ArticleId><ArticleId IdType="pmc">PMC7758411</ArticleId><ArticleId IdType="pubmed">33361764</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson MW, Lima F, Moraes CRP, Ilich A, Huber SC, Barbosa MS, et al. Contact and intrinsic coagulation pathways are activated and associated with adverse clinical outcomes in COVID-19. Blood Adv. 2022;6(11):3367&#x2013;3377. doi: 10.1182/bloodadvances.2021006620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006620</ArticleId><ArticleId IdType="pmc">PMC8893951</ArticleId><ArticleId IdType="pubmed">35235941</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover SP, Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709&#x2013;725. doi: 10.1161/ATVBAHA.117.309846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.117.309846</ArticleId><ArticleId IdType="pubmed">29437578</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry GC, Mackman N. Transcriptional regulation of tissue factor expression in human endothelial cells. Arterioscler Thromb Vasc Biol. 1995;15(5):612&#x2013;621. doi: 10.1161/01.atv.15.5.612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.atv.15.5.612</ArticleId><ArticleId IdType="pubmed">7749875</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma R, Cirillo P, Ciccarelli G, Barra G, Conte S, Pellegrino G, et al. Expression of functional tissue factor in activated T-lymphocytes in vitro and in vivo: a possible contribution of immunity to thrombosis? Int J Cardiol. 2016;218:188&#x2013;195. doi: 10.1016/j.ijcard.2016.04.177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.04.177</ArticleId><ArticleId IdType="pubmed">27236113</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal SK, Iakhiaev A, Pendurthi UR, Mohan Rao LV. Acute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol. Blood. 2005;105(1):153&#x2013;160. doi: 10.1182/blood-2004-03-0990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-03-0990</ArticleId><ArticleId IdType="pmc">PMC2835310</ArticleId><ArticleId IdType="pubmed">15328160</ArticleId></ArticleIdList></Reference><Reference><Citation>Musgrave KM, Scott J, Sendama W, Gardner AI, Dewar F, Lake CJ, et al. Tissue factor expression in monocyte subsets during human immunothrombosis, endotoxemia and sepsis. Thromb Res. 2023;228:10&#x2013;20. doi: 10.1016/j.thromres.2023.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2023.05.018</ArticleId><ArticleId IdType="pubmed">37263122</ArticleId></ArticleIdList></Reference><Reference><Citation>Kothari H, Pendurthi UR, Rao LVM. Analysis of tissue factor expression in various cell model systems: cryptic vs. active. J Thromb Haemost. 2013;11(7):1353&#x2013;1363. doi: 10.1111/jth.12272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.12272</ArticleId><ArticleId IdType="pmc">PMC3900323</ArticleId><ArticleId IdType="pubmed">23621622</ArticleId></ArticleIdList></Reference><Reference><Citation>Owens AP, Mackman N. Role of tissue factor in atherothrombosis. Curr Atheroscler Rep. 2012;14(5):394&#x2013;401. doi: 10.1007/s11883-012-0269-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11883-012-0269-5</ArticleId><ArticleId IdType="pmc">PMC5886738</ArticleId><ArticleId IdType="pubmed">22886473</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108(5):1447&#x2013;1452. doi: 10.1213/ane.0b013e31819bceb1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ane.0b013e31819bceb1</ArticleId><ArticleId IdType="pmc">PMC2838713</ArticleId><ArticleId IdType="pubmed">19372318</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard TJ, Broze GJ. Tissue factor pathway inhibitor. Methods Enzymol. 1993;222:195&#x2013;209. doi: 10.1016/0076-6879(93)22014-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0076-6879(93)22014-7</ArticleId><ArticleId IdType="pubmed">8412794</ArticleId></ArticleIdList></Reference><Reference><Citation>Subrahmanian S, Borczuk A, Salvatore SP, Laurence J, Ahamed J. Higher tissue factor (TF) expression in the lungs of COVID-19 pneumonia patients than patients with acute respiratory distress syndrome: association with thrombi formation. Blood. 2020;136:4. doi: 10.1182/blood-2020-142827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2020-142827</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Subrahmanian S, Borczuk A, Salvatore S, Fung K, Merrill JT, Laurence J, et al. Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. J Thromb Haemost. 2021;19(9):2268&#x2013;2274. doi: 10.1111/jth.15451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15451</ArticleId><ArticleId IdType="pmc">PMC8565501</ArticleId><ArticleId IdType="pubmed">34236752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimento Conde J, Schutt WR, Gorbunova EE, Mackow ER. Recombinant ACE2 expression is required for SARS-CoV-2 To infect primary human endothelial cells and induce inflammatory and procoagulative responses. MBio. 2020;11(6):3185. doi: 10.1128/mBio.03185-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.03185-20</ArticleId><ArticleId IdType="pmc">PMC7751258</ArticleId><ArticleId IdType="pubmed">33310781</ArticleId></ArticleIdList></Reference><Reference><Citation>FitzGerald ES, Chen Y, Fitzgerald KA, Jamieson AM. Lung epithelial cell transcriptional regulation as a factor in COVID-19-associated coagulopathies. Am J Respir Cell Mol Biol. 2021;64(6):687&#x2013;697. doi: 10.1165/rcmb.2020-0453OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2020-0453OC</ArticleId><ArticleId IdType="pmc">PMC8456886</ArticleId><ArticleId IdType="pubmed">33740387</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachetto ATA, Mackman N. Tissue factor and COVID-19: an update. Curr Drug Targets. 2022;23(17):1573&#x2013;1577. doi: 10.2174/1389450123666220926144432.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450123666220926144432</ArticleId><ArticleId IdType="pubmed">36165519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg JB, Foster PA, Kaufman RJ, Vokac EA, Moussalli M, Kroner PA, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998;101(3):613&#x2013;624. doi: 10.1172/JCI1250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI1250</ArticleId><ArticleId IdType="pmc">PMC508605</ArticleId><ArticleId IdType="pubmed">9449695</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover SP, Mackman N. Intrinsic pathway of coagulation and thrombosis. Arterioscler Thromb Vasc Biol. 2019;39(3):331&#x2013;338. doi: 10.1161/ATVBAHA.118.312130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.118.312130</ArticleId><ArticleId IdType="pubmed">30700128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazurkiewicz-Pisarek A, P&#x142;ucienniczak G, Ciach T, P&#x142;ucienniczak A. The factor VIII protein and its function. Acta Biochim Pol. 2016;63(1):11&#x2013;16. doi: 10.18388/abp.2015_1056.</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2015_1056</ArticleId><ArticleId IdType="pubmed">26824291</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogami K, Shima M, Hosokawa K, Suzuki T, Koide T, Saenko EL, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274(43):31000&#x2013;31007. doi: 10.1074/jbc.274.43.31000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.43.31000</ArticleId><ArticleId IdType="pubmed">10521497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;n-Rojas RM, P&#xe9;rez-Rus G, Delgado-Pinos VE, Domingo-Gonz&#xe1;lez A, Regalado-Artamendi I, Alba-Urdiales N, et al. COVID-19 coagulopathy: an in-depth analysis of the coagulation system. Eur J Haematol. 2020;105(6):741&#x2013;750. doi: 10.1111/ejh.13501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejh.13501</ArticleId><ArticleId IdType="pmc">PMC7436538</ArticleId><ArticleId IdType="pubmed">32749010</ArticleId></ArticleIdList></Reference><Reference><Citation>Voicu S, Delrue M, Chousterman BG, St&#xe9;panian A, Bonnin P, Malissin I, et al. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications. Eur Rev Med Pharmacol Sci. 2020;24(17):9161&#x2013;9168. doi: 10.26355/eurrev_202009_22866.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202009_22866</ArticleId><ArticleId IdType="pubmed">32965009</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd El-Lateef AE, Alghamdi S, Ebid G, Khalil K, Kabrah S, Abdel Ghafar MT. Coagulation profile in COVID-19 patients and its relation to disease severity and overall survival: a single-center study. Br J Biomed Sci. 2022;79:10098. doi: 10.3389/bjbs.2022.10098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/bjbs.2022.10098</ArticleId><ArticleId IdType="pmc">PMC9302539</ArticleId><ArticleId IdType="pubmed">35996516</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N, Heightman M, Hillman T, Wall E, Bell R, Kessler A, et al. Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv. 2022;6(13):4041&#x2013;4048. doi: 10.1182/bloodadvances.2021006944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006944</ArticleId><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="pubmed">35543533</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolai L, Kaiser R, Stark K. Thromboinflammation in long COVID&#x2014;the elusive key to postinfection sequelae? J Thromb Haemost. 2023 doi: 10.1016/j.jtha.2023.04.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2023.04.039</ArticleId><ArticleId IdType="pmc">PMC10174338</ArticleId><ArticleId IdType="pubmed">37178769</ArticleId></ArticleIdList></Reference><Reference><Citation>Duminuco A, Calagna M, Markovic U, Esposito B, Grasso S, Riccobene C, et al. Acquired hemophilia A following COVID-19 vaccination&#x2014;the importance of prompt diagnosis: a case report. Transfus Apher Sci. 2022 doi: 10.1016/j.transci.2022.103577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2022.103577</ArticleId><ArticleId IdType="pmc">PMC9465488</ArticleId><ArticleId IdType="pubmed">36151008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollerbach A, M&#xfc;ller-Calleja N, Pedrosa D, Canisius A, Sprinzl MF, Falter T, et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost. 2021;19(9):2335&#x2013;2347. doi: 10.1111/jth.15455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15455</ArticleId><ArticleId IdType="pmc">PMC8420426</ArticleId><ArticleId IdType="pubmed">34242469</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch MH, Timmermans SAMEG, Nagy M, Visser M, Huckriede J, Aendekerk JP, et al. Neutrophils and contact activation of coagulation as potential drivers of COVID-19. Circulation. 2020;142(18):1787&#x2013;1790. doi: 10.1161/CIRCULATIONAHA.120.050656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050656</ArticleId><ArticleId IdType="pmc">PMC7594534</ArticleId><ArticleId IdType="pubmed">32946302</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryant JW, Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem. 2009;7(3):234&#x2013;250. doi: 10.2174/187152509789105444.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152509789105444</ArticleId><ArticleId IdType="pmc">PMC4905712</ArticleId><ArticleId IdType="pubmed">19689262</ArticleId></ArticleIdList></Reference><Reference><Citation>Didiasova M, Wujak L, Schaefer L, Wygrecka M. Factor XII in coagulation, inflammation and beyond. Cell Signal. 2018;51:257&#x2013;265. doi: 10.1016/j.cellsig.2018.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2018.08.006</ArticleId><ArticleId IdType="pubmed">30118759</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcondes S, Antunes E. The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(1):33&#x2013;44. doi: 10.2174/1568016052773351.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568016052773351</ArticleId><ArticleId IdType="pubmed">15638742</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfaro E, D&#xed;az-Garc&#xed;a E, Garc&#xed;a-Tovar S, Zamarr&#xf3;n E, Mangas A, Galera R, et al. Impaired kallikrein-kinin system in COVID-19 patients' severity. Front Immunol. 2022;13:909342. doi: 10.3389/fimmu.2022.909342.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.909342</ArticleId><ArticleId IdType="pmc">PMC9258198</ArticleId><ArticleId IdType="pubmed">35812405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipcsey M, Persson B, Eriksson O, Blom AM, Fromell K, Hultstr&#xf6;m M, et al. The outcome of critically Ill COVID-19 patients is linked to thromboinflammation dominated by the Kallikrein/Kinin system. Front Immunol. 2021;12:627579. doi: 10.3389/fimmu.2021.627579.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.627579</ArticleId><ArticleId IdType="pmc">PMC7937878</ArticleId><ArticleId IdType="pubmed">33692801</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR. Contribution of platelet versus endothelial VWF to platelet adhesion and hemostasis. J Thromb Haemost. 2012;10(8):1646&#x2013;1652. doi: 10.1111/j.1538-7836.2012.04797.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2012.04797.x</ArticleId><ArticleId IdType="pmc">PMC3419786</ArticleId><ArticleId IdType="pubmed">22642380</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhenne S, Denorme F, Libbrecht S, Vandenbulcke A, Pareyn I, Deckmyn H, et al. Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. Blood. 2015;126(14):1715&#x2013;1722. doi: 10.1182/blood-2015-03-632901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-03-632901</ArticleId><ArticleId IdType="pubmed">26209660</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional architecture of weibel-palade bodies. Blood. 2011;117(19):5033&#x2013;5043. doi: 10.1182/blood-2010-09-267492.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-09-267492</ArticleId><ArticleId IdType="pmc">PMC3109530</ArticleId><ArticleId IdType="pubmed">21266719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SE, Curley GF, Lavin M, Fogarty H, Karampini E, McEvoy NL, et al. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2021;192(4):714&#x2013;719. doi: 10.1111/bjh.17273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17273</ArticleId><ArticleId IdType="pubmed">33326604</ArticleId></ArticleIdList></Reference><Reference><Citation>Wibowo A, Pranata R, Lim MA, Akbara MR, Martha JW. Endotheliopathy marked by high von Willebrand factor (vWF) antigen in COVID-19 is associated with poor outcome: a systematic review and meta-analysis. Int J Infect Dis. 2022;117:267&#x2013;273. doi: 10.1016/j.ijid.2021.06.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.06.051</ArticleId><ArticleId IdType="pmc">PMC8236128</ArticleId><ArticleId IdType="pubmed">34192577</ArticleId></ArticleIdList></Reference><Reference><Citation>Karampini E, Fogarty H, Elliott S, Morrin H, Bergin C, O'Sullivan JM, et al. Endothelial cell activation, Weibel-Palade body secretion, and enhanced angiogenesis in severe COVID-19. Res Pract Thromb Haemost. 2023;7(2):100085. doi: 10.1016/j.rpth.2023.100085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpth.2023.100085</ArticleId><ArticleId IdType="pmc">PMC9927806</ArticleId><ArticleId IdType="pubmed">36817284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng XL. ADAMTS13 and von willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med. 2015;66:211&#x2013;225. doi: 10.1146/annurev-med-061813-013241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-061813-013241</ArticleId><ArticleId IdType="pmc">PMC4599565</ArticleId><ArticleId IdType="pubmed">25587650</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancini I, Baronciani L, Artoni A, Colpani P, Biganzoli M, Cozzi G, et al. The ADAMTS13-von willebrand factor axis in COVID-19 patients. J Thromb Haemost. 2021;19(2):513&#x2013;521. doi: 10.1111/jth.15191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15191</ArticleId><ArticleId IdType="pmc">PMC7753796</ArticleId><ArticleId IdType="pubmed">33230904</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Feng Y, Jia Y, Zhang X, Li L, Bai X, et al. Prognostic value of von willebrand factor and ADAMTS13 in patients with COVID-19: a systematic review and meta-analysis. Thromb Res. 2022;218:83&#x2013;98. doi: 10.1016/j.thromres.2022.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.08.017</ArticleId><ArticleId IdType="pmc">PMC9385270</ArticleId><ArticleId IdType="pubmed">36027630</ArticleId></ArticleIdList></Reference><Reference><Citation>Mei ZW, van Wijk Xander MR, Pham HP, Marin MJ. Role of von willebrand factor in COVID-19 associated coagulopathy. J Appl Lab Med. 2021;6(5):1305&#x2013;1315. doi: 10.1093/jalm/jfab042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jalm/jfab042</ArticleId><ArticleId IdType="pmc">PMC8135722</ArticleId><ArticleId IdType="pubmed">33930144</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah H, Kim A, Sukumar S, Mazepa M, Kohli R, Braunstein EM, et al. SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura. Blood. 2022;139(16):2570&#x2013;2573. doi: 10.1182/blood.2022015545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022015545</ArticleId><ArticleId IdType="pmc">PMC8906888</ArticleId><ArticleId IdType="pubmed">35259252</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H, Ward SE, Townsend L, Karampini E, Elliott S, Conlon N, et al. Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction. J Thromb Haemost. 2022;20(10):2429&#x2013;2438. doi: 10.1111/jth.15830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15830</ArticleId><ArticleId IdType="pmc">PMC9349977</ArticleId><ArticleId IdType="pubmed">35875995</ArticleId></ArticleIdList></Reference><Reference><Citation>Medcalf RL, Keragala CB. The fibrinolytic system: mysteries and opportunities. Hemasphere. 2021;5(6):e570. doi: 10.1097/HS9.0000000000000570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/HS9.0000000000000570</ArticleId><ArticleId IdType="pmc">PMC8171360</ArticleId><ArticleId IdType="pubmed">34095754</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubauer K, Zieger B. Endothelial cells and coagulation. Cell Tissue Res. 2022;387(3):391&#x2013;398. doi: 10.1007/s00441-021-03471-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-021-03471-2</ArticleId><ArticleId IdType="pmc">PMC8975780</ArticleId><ArticleId IdType="pubmed">34014399</ArticleId></ArticleIdList></Reference><Reference><Citation>Keragala CB, Medcalf RL, Myles PS. Fibrinolysis and COVID-19: a tale of two sites? J Thromb Haemost. 2020;18(9):2430&#x2013;2432. doi: 10.1111/jth.15017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15017</ArticleId><ArticleId IdType="pmc">PMC7404869</ArticleId><ArticleId IdType="pubmed">32692877</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Warnock M, Harbaugh A, Yalavarthi S, Gockman K, Zuo M, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep. 2021;11(1):1580. doi: 10.1038/s41598-020-80010-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80010-z</ArticleId><ArticleId IdType="pmc">PMC7810990</ArticleId><ArticleId IdType="pubmed">33452298</ArticleId></ArticleIdList></Reference><Reference><Citation>Nougier C, Benoit R, Simon M, Desmurs-Clavel H, Marcotte G, Argaud L, et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost. 2020;18(9):2215&#x2013;2219. doi: 10.1111/jth.15016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15016</ArticleId><ArticleId IdType="pmc">PMC7405476</ArticleId><ArticleId IdType="pubmed">32668058</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Garcia D, Miltiades A, Yim P, Parsons S, Elisman K, Mansouri MT, et al. Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. Int J Hematol. 2022;116(6):937&#x2013;946. doi: 10.1007/s12185-022-03437-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-022-03437-2</ArticleId><ArticleId IdType="pmc">PMC9395834</ArticleId><ArticleId IdType="pubmed">35994163</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy RD, Nithin Kuriakose N, Vijaykrishnaraj MN, Patil P, Jayaswamy PK, Alagundagi DB, et al. Tissue plasminogen activator receptor ANXA2 and its complementary regulator anti-inflammatory ANXA1 as prognostic indicators of inflammatory response in COVID-19 pathogenesis. Immunobiology. 2023;228(5):152728. doi: 10.1016/j.imbio.2023.152728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2023.152728</ArticleId><ArticleId IdType="pubmed">37579635</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos Silva BR, Poblete Jara C, Sidarta-Oliveira D, Velloso LA, Velander WH, Ara&#xfa;jo EP. Downregulation of the protein C signaling system is associated with COVID-19 hypercoagulability-A single-cell transcriptomics analysis. Viruses. 2022;14(12):2753. doi: 10.3390/v14122753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122753</ArticleId><ArticleId IdType="pmc">PMC9785999</ArticleId><ArticleId IdType="pubmed">36560757</ArticleId></ArticleIdList></Reference><Reference><Citation>Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007;13(11):1349&#x2013;1358. doi: 10.1038/nm1667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1667</ArticleId><ArticleId IdType="pubmed">17982464</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan N, Heightman M, Hillman T, Wall E, Bell R, Kessler A, et al. Impaired exercise capacity in post&#x2013;COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv. 2022;6(13):4041&#x2013;4048. doi: 10.1182/bloodadvances.2021006944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021006944</ArticleId><ArticleId IdType="pmc">PMC9098525</ArticleId><ArticleId IdType="pubmed">35543533</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) Cardiovasc Diabetol. 2022;21(1):148. doi: 10.1186/s12933-022-01579-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvet L, Thouy F, Mascle O, Sapin A, Grapin K, Liteaudon JM, et al. Hypercoagulability in critically ill patients with COVID 19, an observational prospective study. PLoS ONE. 2022;17(11):e0277544. doi: 10.1371/journal.pone.0277544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0277544</ArticleId><ArticleId IdType="pmc">PMC9683576</ArticleId><ArticleId IdType="pubmed">36417476</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba&#xf1;ez C, Perdomo J, Calvo A, Ferrando C, Reverter JC, Tassies D, et al. High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? J Thromb Thrombolysis. 2021;51(2):308&#x2013;312. doi: 10.1007/s11239-020-02226-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02226-0</ArticleId><ArticleId IdType="pmc">PMC7363162</ArticleId><ArticleId IdType="pubmed">32671609</ArticleId></ArticleIdList></Reference><Reference><Citation>Baycan OF, Barman HA, Bolen F, Atici A, Erman H, Korkmaz R, et al. Plasminogen activator inhibitor-1 levels as an indicator of severity and mortality for COVID-19. North Clin Istanb. 2023;10(1):1&#x2013;9. doi: 10.14744/nci.2022.09076.</Citation><ArticleIdList><ArticleId IdType="doi">10.14744/nci.2022.09076</ArticleId><ArticleId IdType="pmc">PMC9996651</ArticleId><ArticleId IdType="pubmed">36910430</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen ND, Rollins-Raval MA, Raval JS, Thachil J. Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19? Thromb Res. 2022;210:1&#x2013;3. doi: 10.1016/j.thromres.2021.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.12.012</ArticleId><ArticleId IdType="pmc">PMC8686202</ArticleId><ArticleId IdType="pubmed">34953317</ArticleId></ArticleIdList></Reference><Reference><Citation>diabetes Lw, Policy P. IDF Diabetes Atlas | Tenth Edition. https://diabetesatlas.org/. Accessed 8 Oct 2023.</Citation></Reference><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int. Accessed 8 Oct 2023.</Citation></Reference><Reference><Citation>Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically Ill patients in the seattle region&#x2014;case series. N Engl J Med. 2020;382(21):2012&#x2013;2022. doi: 10.1056/NEJMoa2004500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2004500</ArticleId><ArticleId IdType="pmc">PMC7143164</ArticleId><ArticleId IdType="pubmed">32227758</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncon L, Zuin M, Rigatelli G, Zuliani G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J Clin Virol. 2020;127:104354. doi: 10.1016/j.jcv.2020.104354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104354</ArticleId><ArticleId IdType="pmc">PMC7195018</ArticleId><ArticleId IdType="pubmed">32305882</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr. 2020;14(4):535&#x2013;545. doi: 10.1016/j.dsx.2020.04.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.04.044</ArticleId><ArticleId IdType="pmc">PMC7200339</ArticleId><ArticleId IdType="pubmed">32408118</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Shen M, Yang Q, Fairley CK, Chai Z, McIntyre R, et al. Global diabetes prevalence in COVID-19 patients and contribution to COVID-19- related severity and mortality: a systematic review and meta-analysis. Diabetes Care. 2023;46(4):890&#x2013;897. doi: 10.2337/dc22-1943.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-1943</ArticleId><ArticleId IdType="pmc">PMC10090902</ArticleId><ArticleId IdType="pubmed">36826982</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahamat-Saleh Y, Fiolet T, Rebeaud ME, Mulot M, Guihur A, El Fatouhi D, et al. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. BMJ Open. 2021;11(10):e052777. doi: 10.1136/bmjopen-2021-052777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-052777</ArticleId><ArticleId IdType="pmc">PMC8557249</ArticleId><ArticleId IdType="pubmed">34697120</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding JL, Oviedo SA, Ali MK, Ofotokun I, Gander JC, Patel SA, et al. The bidirectional association between diabetes and long-COVID-19&#x2014;a systematic review. Diabetes Res Clin Pract. 2023;195:110202. doi: 10.1016/j.diabres.2022.110202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2022.110202</ArticleId><ArticleId IdType="pmc">PMC9727969</ArticleId><ArticleId IdType="pubmed">36496030</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43(7):1408&#x2013;1415. doi: 10.2337/dc20-0723.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-0723</ArticleId><ArticleId IdType="pmc">PMC7305003</ArticleId><ArticleId IdType="pubmed">32430456</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7):e3319. doi: 10.1002/dmrr.3319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3319</ArticleId><ArticleId IdType="pmc">PMC7228407</ArticleId><ArticleId IdType="pubmed">32233013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, She Z, Cheng X, Qin J, Zhang X, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068&#x2013;1077.e3. doi: 10.1016/j.cmet.2020.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.04.021</ArticleId><ArticleId IdType="pmc">PMC7252168</ArticleId><ArticleId IdType="pubmed">32369736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, Nicklas JM, Puskarich MA, Cohen K, et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;23(10):1119&#x2013;1129. doi: 10.1016/S1473-3099(23)00299-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00299-2</ArticleId><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong L, Xiao X, Li M, Fang S, Ma E, Yu X, et al. A glucose-like metabolite deficient in diabetes inhibits cellular entry of SARS-CoV-2. Nat Metab. 2022;4(5):547&#x2013;558. doi: 10.1038/s42255-022-00567-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-022-00567-z</ArticleId><ArticleId IdType="pubmed">35534727</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10(5):311&#x2013;321. doi: 10.1016/S2213-8587(22)00044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18(9):2128&#x2013;2130.e2. doi: 10.1016/j.cgh.2020.04.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2020.04.040</ArticleId><ArticleId IdType="pmc">PMC7194639</ArticleId><ArticleId IdType="pubmed">32334082</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett FN, Coucha M, Bolduc DR, Hermanns VC, Heath SP, Abdelghani M, et al. SARS-CoV-2 spike protein intensifies cerebrovascular complications in diabetic hACE2 mice through RAAS and TLR signaling activation. Int J Mol Sci. 2023;24(22):16394. doi: 10.3390/ijms242216394.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms242216394</ArticleId><ArticleId IdType="pmc">PMC10671133</ArticleId><ArticleId IdType="pubmed">38003584</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020;43(6):867&#x2013;869. doi: 10.1007/s40618-020-01236-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01236-2</ArticleId><ArticleId IdType="pmc">PMC7103097</ArticleId><ArticleId IdType="pubmed">32222956</ArticleId></ArticleIdList></Reference><Reference><Citation>Polat G, G&#xfc;&#xe7;sav MO, &#xd6;zdemir &#xd6;, T&#xfc;rk MA, Unat DS, Tatar D. The association between glycemia and clinical outcomes in patients with diabetes mellitus and pulmonary thromboembolism. Arch Endocrinol Metab. 2023;67(3):341&#x2013;347. doi: 10.20945/2359-3997000000544.</Citation><ArticleIdList><ArticleId IdType="doi">10.20945/2359-3997000000544</ArticleId><ArticleId IdType="pmc">PMC10247243</ArticleId><ArticleId IdType="pubmed">36651707</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#x119;ca T, Wojtowicz K, Guzik P, G&#xf3;ra T. Increased risk of COVID-19 in patients with diabetes mellitus-current challenges in pathophysiology, treatment and prevention. Int J Environ Res Public Health. 2022;19(11):6555. doi: 10.3390/ijerph19116555.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19116555</ArticleId><ArticleId IdType="pmc">PMC9180541</ArticleId><ArticleId IdType="pubmed">35682137</ArticleId></ArticleIdList></Reference><Reference><Citation>Varikasuvu SR, Varshney S, Dutt N. Markers of coagulation dysfunction and inflammation in diabetic and non-diabetic COVID-19. J Thromb Thrombolysis. 2021;51(4):941&#x2013;946. doi: 10.1007/s11239-020-02270-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02270-w</ArticleId><ArticleId IdType="pmc">PMC7474490</ArticleId><ArticleId IdType="pubmed">32889620</ArticleId></ArticleIdList></Reference><Reference><Citation>Alosaimi B, Mubarak A, Hamed ME, Almutairi AZ, Alrashed AA, AlJuryyan A, et al. Complement anaphylatoxins and inflammatory cytokines as prognostic markers for COVID-19 severity and in-hospital mortality. Front Immunol. 2021;12:668725. doi: 10.3389/fimmu.2021.668725.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.668725</ArticleId><ArticleId IdType="pmc">PMC8281279</ArticleId><ArticleId IdType="pubmed">34276659</ArticleId></ArticleIdList></Reference><Reference><Citation>George TP, Joy SS, Rafiullah M, Siddiqui K. Cytokines involved in COVID-19 patients with diabetes: a systematic review. Curr Diabetes Rev. 2023;19(3):e180122200321. doi: 10.2174/1573399818666220118100743.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573399818666220118100743</ArticleId><ArticleId IdType="pubmed">35040414</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegazzo L, Scattolini V, Cappellari R, Bonora BM, Albiero M, Bortolozzi M, et al. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol. 2018;55(6):593&#x2013;601. doi: 10.1007/s00592-018-1129-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00592-018-1129-8</ArticleId><ArticleId IdType="pubmed">29546579</ArticleId></ArticleIdList></Reference><Reference><Citation>Njeim R, Azar WS, Fares AH, Azar ST, Kfoury Kassouf H, Eid AA. NETosis contributes to the pathogenesis of diabetes and its complications. J Mol Endocrinol. 2020;65(4):R65&#x2013;R76. doi: 10.1530/JME-20-0128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JME-20-0128</ArticleId><ArticleId IdType="pubmed">33048064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, Gao L, Thakur A, Siu PM, Lai CWK. Role of free fatty acids in endothelial dysfunction. J Biomed Sci. 2017;24:50. doi: 10.1186/s12929-017-0357-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-017-0357-5</ArticleId><ArticleId IdType="pmc">PMC5530532</ArticleId><ArticleId IdType="pubmed">28750629</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuschik L, Riabov V, Schmuttermaier C, Sevastyanova T, Weiss C, Kl&#xfc;ter H, et al. Hyperglycemia induces inflammatory response of human macrophages to CD163-mediated scavenging of hemoglobin-haptoglobin complexes. Int J Mol Sci. 2022;23(3):1385. doi: 10.3390/ijms23031385.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031385</ArticleId><ArticleId IdType="pmc">PMC8836198</ArticleId><ArticleId IdType="pubmed">35163309</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of hyperglycemia and diabetes mellitus on coagulation and hemostasis. J Clin Med. 2021;10(11):2419. doi: 10.3390/jcm10112419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112419</ArticleId><ArticleId IdType="pmc">PMC8199251</ArticleId><ArticleId IdType="pubmed">34072487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chourasia P, Goyal L, Kansal D, Roy S, Singh R, Mahata I, et al. Risk of new-onset diabetes mellitus as a post-COVID-19 condition and possible mechanisms: a scoping review. J Clin Med. 2023;12(3):1159. doi: 10.3390/jcm12031159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12031159</ArticleId><ArticleId IdType="pmc">PMC9917823</ArticleId><ArticleId IdType="pubmed">36769807</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvisi SL, Ramirez GA, Scavini M, Da Prat V, Di Lucca G, Laurenzi A, et al. Thromboembolism risk among patients with diabetes/stress hyperglycemia and COVID-19. Metabolism. 2021;123:154845. doi: 10.1016/j.metabol.2021.154845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2021.154845</ArticleId><ArticleId IdType="pmc">PMC8340557</ArticleId><ArticleId IdType="pubmed">34364927</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiattarella GG, Carrizzo A, Ilardi F, Damato A, Ambrosio M, Madonna M, et al. Rac1 modulates endothelial function and platelet aggregation in diabetes mellitus. J Am Heart Assoc. 2018;7(8):e007322. doi: 10.1161/JAHA.117.007322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.117.007322</ArticleId><ArticleId IdType="pmc">PMC6015399</ArticleId><ArticleId IdType="pubmed">29626150</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui K, George TP, Mujammami M, Isnani A, Alfadda AA. The association of cell adhesion molecules and selectins (VCAM-1, ICAM-1, E-selectin, L-selectin, and P-selectin) with microvascular complications in patients with type 2 diabetes: a follow-up study. Front Endocrinol (Lausanne) 2023;14:1072288. doi: 10.3389/fendo.2023.1072288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2023.1072288</ArticleId><ArticleId IdType="pmc">PMC9948618</ArticleId><ArticleId IdType="pubmed">36843591</ArticleId></ArticleIdList></Reference><Reference><Citation>Palella E, Cimino R, Pullano SA, Fiorillo AS, Gulletta E, Brunetti A, et al. Laboratory parameters of hemostasis, adhesion molecules, and inflammation in type 2 diabetes mellitus: correlation with glycemic control. Int J Environ Res Public Health. 2020;17(1):300. doi: 10.3390/ijerph17010300.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17010300</ArticleId><ArticleId IdType="pmc">PMC6982208</ArticleId><ArticleId IdType="pubmed">31906326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HK, Kim JE, Park SH, Kim YI, Nam-Goong IS, Kim ES. High coagulation factor levels and low protein C levels contribute to enhanced thrombin generation in patients with diabetes who do not have macrovascular complications. J Diabetes Complications. 2014;28(3):365&#x2013;369. doi: 10.1016/j.jdiacomp.2014.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2014.01.006</ArticleId><ArticleId IdType="pubmed">24560421</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Toorn FA, de Mutsert R, Lijfering WM, Rosendaal FR, van Hylckama VA. Glucose metabolism affects coagulation factors: the NEO study. J Thromb Haemost. 2019;17(11):1886&#x2013;1897. doi: 10.1111/jth.14573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14573</ArticleId><ArticleId IdType="pubmed">31325222</ArticleId></ArticleIdList></Reference><Reference><Citation>Barillari G, Fabbro E, Pasca S, Bigotto E. Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population. Blood Coagul Fibrinolysis. 2009;20(4):290&#x2013;296. doi: 10.1097/MBC.0b013e328329e49b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0b013e328329e49b</ArticleId><ArticleId IdType="pubmed">19318924</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothschild AM, Reis ML, Melo VL, Foss MC, Gallo L. Increased kininogen levels observed in plasma of diabetic patients are corrected by the administration of insulin. Horm Metab Res. 1999;31(5):326&#x2013;328. doi: 10.1055/s-2007-978746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-978746</ArticleId><ArticleId IdType="pubmed">10422729</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107(7):973&#x2013;977. doi: 10.1161/01.cir.0000050621.67499.7d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.0000050621.67499.7d</ArticleId><ArticleId IdType="pubmed">12600909</ArticleId></ArticleIdList></Reference><Reference><Citation>Kietsiriroje N, Pearson SM, O'Mahoney LL, West DJ, Ari&#xeb;ns RA, Ajjan RA, et al. Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: an observational study. Diab Vasc Dis Res. 2022;19(3):14791641221103217. doi: 10.1177/14791641221103217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/14791641221103217</ArticleId><ArticleId IdType="pmc">PMC9168893</ArticleId><ArticleId IdType="pubmed">35657731</ArticleId></ArticleIdList></Reference><Reference><Citation>De Mattia G, Bravi MC, Laurenti O, Moretti A, Cipriani R, Gatti A, et al. Endothelial dysfunction and oxidative stress in type 1 and type 2 diabetic patients without clinical macrovascular complications. Diabetes Res Clin Pract. 2008;79(2):337&#x2013;342. doi: 10.1016/j.diabres.2007.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2007.09.005</ArticleId><ArticleId IdType="pubmed">17949845</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanesha N, Doddapattar P, Chorawala MR, Nayak MK, Kokame K, Staber JM, et al. ADAMTS13 retards progression of diabetic nephropathy by inhibiting intrarenal thrombosis in mice. Arterioscler Thromb Vasc Biol. 2017;37(7):1332&#x2013;1338. doi: 10.1161/ATVBAHA.117.309539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.117.309539</ArticleId><ArticleId IdType="pmc">PMC5501287</ArticleId><ArticleId IdType="pubmed">28495930</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn EJ, Philippou H, Ari&#xeb;ns RAS, Grant PJ. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia. 2006;49(5):1071&#x2013;1080. doi: 10.1007/s00125-006-0197-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-006-0197-4</ArticleId><ArticleId IdType="pubmed">16538489</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L, Fu Q, Zhou L, Fan Y, Liu F, Fan Y, et al. D-dimer as a predictor of cardiovascular outcomes in patients with diabetes mellitus. BMC Cardiovasc Disord. 2022;22(1):82. doi: 10.1186/s12872-022-02531-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-022-02531-x</ArticleId><ArticleId IdType="pmc">PMC8895572</ArticleId><ArticleId IdType="pubmed">35246061</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013;122(1):134&#x2013;142. doi: 10.1182/blood-2013-04-494641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-04-494641</ArticleId><ArticleId IdType="pubmed">23699598</ArticleId></ArticleIdList></Reference><Reference><Citation>Uitte de Willige S, Malfliet Joyce JCM, Abdul S, Leebeek FWG, Rijken DC. The level of circulating fibroblast activation protein correlates with incorporation of alpha-2-antiplasmin into the fibrin clot. Thromb Res. 2018;166:19&#x2013;21. doi: 10.1016/j.thromres.2018.03.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2018.03.018</ArticleId><ArticleId IdType="pubmed">29649768</ArticleId></ArticleIdList></Reference><Reference><Citation>Agren A, J&#xf6;rneskog G, Elgue G, Henriksson P, Wallen H, Wiman B. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes Care. 2014;37(7):2007&#x2013;2014. doi: 10.2337/dc13-1776.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc13-1776</ArticleId><ArticleId IdType="pubmed">24760258</ArticleId></ArticleIdList></Reference><Reference><Citation>Akwiwu E, Edem M, Akpotuzor J, Asemota E, Isong I. Glycated haemogloin, fasting plasma glucose, plasminogen activator inhibitor type-1, and soluble thrombomodulin levels in patients with type 2 diabetes mellitus. Niger J Physiol Sci. 2021;36(2):159&#x2013;164. doi: 10.54548/njps.v36i2.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.54548/njps.v36i2.3</ArticleId><ArticleId IdType="pubmed">35947738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, et al. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res Clin Pract. 2006;73(2):150&#x2013;157. doi: 10.1016/j.diabres.2005.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2005.12.008</ArticleId><ArticleId IdType="pubmed">16458385</ArticleId></ArticleIdList></Reference><Reference><Citation>Miri C, Charii H, Bouazzaoui M, Laouan Brem F, Boulouiz S, Abda N, et al. D-dimer level and diabetes in the COVID-19 infection. Clin Appl Thromb Hemost. 2021;27:10760296211045902. doi: 10.1177/10760296211045902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10760296211045902</ArticleId><ArticleId IdType="pmc">PMC8495508</ArticleId><ArticleId IdType="pubmed">34590493</ArticleId></ArticleIdList></Reference><Reference><Citation>Iskandar A, Mayashinta DK, Robert R, Samsu N, Endharti AT, Widjajanto E. Correlation between IL-8, C-reactive proteins (CRP) and neutrophil to lymphocyte ratio (NLR) as predictor of mortality in COVID-19 patients with diabetes mellitus comorbidity. Int J Gen Med. 2023;16:2349&#x2013;2354. doi: 10.2147/IJGM.S412070.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S412070</ArticleId><ArticleId IdType="pmc">PMC10259590</ArticleId><ArticleId IdType="pubmed">37313045</ArticleId></ArticleIdList></Reference><Reference><Citation>Francischetti IMB, Toomer K, Zhang Y, Jani J, Siddiqui Z, Brotman DJ, et al. Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection. EClinicalMedicine. 2021;39:101069. doi: 10.1016/j.eclinm.2021.101069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101069</ArticleId><ArticleId IdType="pmc">PMC8342934</ArticleId><ArticleId IdType="pubmed">34377969</ArticleId></ArticleIdList></Reference><Reference><Citation>Soma P, Swanepoel AC, Bester J, Pretorius E. Tissue factor levels in type 2 diabetes mellitus. Inflamm Res. 2017;66(5):365&#x2013;368. doi: 10.1007/s00011-017-1030-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-017-1030-x</ArticleId><ArticleId IdType="pubmed">28246677</ArticleId></ArticleIdList></Reference><Reference><Citation>Masi P, H&#xe9;kimian G, Lejeune M, Chommeloux J, Desnos C, Pineton De Chambrun M, et al. Systemic inflammatory response syndrome is a major contributor to COVID-19-associated coagulopathy: insights from a prospective, single-center cohort study. Circulation. 2020;142(6):611&#x2013;614. doi: 10.1161/CIRCULATIONAHA.120.048925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048925</ArticleId><ArticleId IdType="pmc">PMC7418760</ArticleId><ArticleId IdType="pubmed">32776849</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Cao W, Jiang W, Xiao M, Li Y, Tang N, et al. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis. 2020;50(3):580&#x2013;586. doi: 10.1007/s11239-020-02182-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02182-9</ArticleId><ArticleId IdType="pmc">PMC7346854</ArticleId><ArticleId IdType="pubmed">32648093</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedzierska K, Ciechanowski K, Go&#x142;embiewska E, Safranow K, Ciechanowicz A, Doma&#x144;ski L, et al. Plasma prekallikrein as a risk factor for diabetic retinopathy. Arch Med Res. 2005;36(5):539&#x2013;543. doi: 10.1016/j.arcmed.2005.03.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2005.03.050</ArticleId><ArticleId IdType="pubmed">16099335</ArticleId></ArticleIdList></Reference><Reference><Citation>Colhoun HM, Zito F, Norman Chan N, Rubens MB, Fuller JH, Humphries SE. Activated factor XII levels and factor XII 46C&gt;T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis. 2002;163(2):363&#x2013;369. doi: 10.1016/s0021-9150(02)00022-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0021-9150(02)00022-9</ArticleId><ArticleId IdType="pubmed">12052484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceballos FC, Ryan P, Blancas R, Martin-Vicente M, Vidal-Alc&#xe1;ntara EJ, Per&#xe9;z-Garc&#xed;a F, et al. Are reduced levels of coagulation proteins upon admission linked to COVID-19 severity and mortality? Front Med. 2021;8:718053. doi: 10.3389/fmed.2021.718053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.718053</ArticleId><ArticleId IdType="pmc">PMC8514618</ArticleId><ArticleId IdType="pubmed">34660629</ArticleId></ArticleIdList></Reference><Reference><Citation>Paszek E, Polak M, Bryk-Wi&#x105;zania AH, Konieczy&#x144;ska M, Undas A. Elevated plasma factor XI predicts cardiovascular events in patients with type 2 diabetes: a long-term observational study. Cardiovasc Diabetol. 2023;22(1):182. doi: 10.1186/s12933-023-01905-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01905-5</ArticleId><ArticleId IdType="pmc">PMC10353137</ArticleId><ArticleId IdType="pubmed">37460982</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089&#x2013;1098. doi: 10.1007/s00134-020-06062-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-06062-x</ArticleId><ArticleId IdType="pmc">PMC7197634</ArticleId><ArticleId IdType="pubmed">32367170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ephraim RK, Awuku YA, Adu P, Ampomah LT, Adoba P, Panford S, et al. High risk of coagulopathy among Type-2 diabetes mellitus clients at a municipal hospital in Ghana. Ghana Med J. 2017;51(3):101&#x2013;107. doi: 10.4314/gmj.v51i3.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.4314/gmj.v51i3.2</ArticleId><ArticleId IdType="pmc">PMC5870234</ArticleId><ArticleId IdType="pubmed">29622820</ArticleId></ArticleIdList></Reference><Reference><Citation>Althaus K, Marini I, Zlamal J, Pelzl L, Singh A, H&#xe4;berle H, et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021;137(8):1061&#x2013;1071. doi: 10.1182/blood.2020008762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008762</ArticleId><ArticleId IdType="pmc">PMC7791311</ArticleId><ArticleId IdType="pubmed">33512415</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti M, Gomez-Rosas P, Russo L, Gamba S, Sanga E, Verzeroli C, et al. Fibrinolytic proteins and factor XIII as predictors of thrombotic and hemorrhagic complications in hospitalized COVID-19 patients. Front Cardiovasc Med. 2022;9:896362. doi: 10.3389/fcvm.2022.896362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.896362</ArticleId><ArticleId IdType="pmc">PMC9226333</ArticleId><ArticleId IdType="pubmed">35757331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauls DL, Banini AE, Boyd LC, Hoffman M. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. J Thromb Haemost. 2007;5(3):638&#x2013;639. doi: 10.1111/j.1538-7836.2007.02366.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2007.02366.x</ArticleId><ArticleId IdType="pubmed">17166250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Zhang J, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS ONE. 2011;6(1):e16470. doi: 10.1371/journal.pone.0016470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0016470</ArticleId><ArticleId IdType="pmc">PMC3030587</ArticleId><ArticleId IdType="pubmed">21297995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui J, Noubouossie DF, Gandotra S, Cao L. Elevated plasma fibrinogen is associated with excessive inflammation and disease severity in COVID-19 patients. Front Cell Infect Microbiol. 2021;11:734005. doi: 10.3389/fcimb.2021.734005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.734005</ArticleId><ArticleId IdType="pmc">PMC8369350</ArticleId><ArticleId IdType="pubmed">34414135</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansfield MW, Kohler HP, Ari&#xeb;ns RA, McCormack LJ, Grant PJ. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. Diabetes Care. 2000;23(5):703&#x2013;705. doi: 10.2337/diacare.23.5.703.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.23.5.703</ArticleId><ArticleId IdType="pubmed">10834435</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichter Y, Badelbayov T, Shalev I, Schvartz R, Szekely Y, Benisty D, et al. Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients. Thromb J. 2021;19(1):79. doi: 10.1186/s12959-021-00333-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-021-00333-3</ArticleId><ArticleId IdType="pmc">PMC8567130</ArticleId><ArticleId IdType="pubmed">34736472</ArticleId></ArticleIdList></Reference><Reference><Citation>Medina MG, Ledesma MD, Dom&#xed;nguez JE, Medina M, Zafra D, Alameda F, et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J. 2005;24(9):1706&#x2013;1716. doi: 10.1038/sj.emboj.7600650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7600650</ArticleId><ArticleId IdType="pmc">PMC1142582</ArticleId><ArticleId IdType="pubmed">15861134</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrianto N, Al-Farabi MJ, Nugraha RA, Marsudi BA, Azmi Y. Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Microvasc Res. 2021;138:104224. doi: 10.1016/j.mvr.2021.104224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2021.104224</ArticleId><ArticleId IdType="pmc">PMC8279939</ArticleId><ArticleId IdType="pubmed">34273359</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res. 1992;67(6):643&#x2013;654. doi: 10.1016/0049-3848(92)90068-l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-3848(92)90068-l</ArticleId><ArticleId IdType="pubmed">1440530</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Morte D, Pacifici F, Ricordi C, Massoud R, Rovella V, Proietti S, et al. Low level of plasminogen increases risk for mortality in COVID-19 patients. Cell Death Dis. 2021;12(8):773. doi: 10.1038/s41419-021-04070-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04070-3</ArticleId><ArticleId IdType="pmc">PMC8340078</ArticleId><ArticleId IdType="pubmed">34354045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouck EG, Denorme F, Holle LA, Middelton EA, Blair AM, de Laat B, et al. COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity. Arterioscler Thromb Vasc Biol. 2021;41(1):401&#x2013;414. doi: 10.1161/ATVBAHA.120.315338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315338</ArticleId><ArticleId IdType="pmc">PMC7942774</ArticleId><ArticleId IdType="pubmed">33196292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokn&#xe4;s N, Laine C, Hillarp A, Macwan AS, Gustafsson KM, Lindahl TL, et al. Associations between hemostatic markers and mortality in COVID-19&#x2014;compounding effects of D-dimer, antithrombin and PAP complex. Thromb Res. 2022;213:97&#x2013;104. doi: 10.1016/j.thromres.2022.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.03.013</ArticleId><ArticleId IdType="pmc">PMC8930184</ArticleId><ArticleId IdType="pubmed">35316719</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jongh R, Ninivaggi M, Mesotten D, Bai C, Marcus B, Huskens D, et al. Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU. Blood Coagul Fibrinolysis. 2021;32(4):290&#x2013;293. doi: 10.1097/MBC.0000000000001007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0000000000001007</ArticleId><ArticleId IdType="pubmed">33443932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang L, Yu C, Xu F, Zhao L, Wang X, Wang C, et al. Increased plasma D-dimer levels may be a promising indicator for diabetic peripheral neuropathy in type 2 diabetes. Front Endocrinol. 2022;13:930271. doi: 10.3389/fendo.2022.930271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.930271</ArticleId><ArticleId IdType="pmc">PMC9445160</ArticleId><ArticleId IdType="pubmed">36082076</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Garc&#xed;a N, Garc&#xed;a-Gonz&#xe1;lez J, Requena-Mullor M, Rodr&#xed;guez-Maresca M&#xc1;, Alarc&#xf3;n-Rodr&#xed;guez R. Comparison of analytical values D-Dimer, glucose, ferritin and C-reactive protein of symptomatic and asymptomatic COVID-19 patients. Int J Environ Res Public Health. 2022;19(9):5354. doi: 10.3390/ijerph19095354.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19095354</ArticleId><ArticleId IdType="pmc">PMC9102188</ArticleId><ArticleId IdType="pubmed">35564749</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukahori S, Han JY, Vera I, Lockey R, Kim K, Cho S. Elevated PAI-1 levels are associated with severe COVID-19. J Allergy Clin Immunol. 2023;151(2):190. doi: 10.1016/j.jaci.2022.12.595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.12.595</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandolfi A, Cetrullo D, Polishuck R, Alberta MM, Calafiore A, Pellegrini G, et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol. 2001;21(8):1378&#x2013;1382. doi: 10.1161/hq0801.093667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hq0801.093667</ArticleId><ArticleId IdType="pubmed">11498469</ArticleId></ArticleIdList></Reference><Reference><Citation>Agosti F, Toffolutti V, Cavalli N, Nivakoski S, Mascherini M, Aassve A. Information and vaccine hesitancy: Evidence from the early stage of the vaccine roll-out in 28 European countries. PLoS One. 2022;17(9):e0273555. 10.1371/journal.pone.0273555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491558</ArticleId><ArticleId IdType="pubmed">36129897</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gregorio C, Calcaterra G, Kounis NG, Bassareo PP, Mehta JL. Cerebral venous thrombosis after COVID-19 vaccines: Do we know the mechanism? Lancet Reg Health Eur. 2022;16:100387. 10.1016/j.lanepe.2022.100387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9008443</ArticleId><ArticleId IdType="pubmed">35437521</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla M, Canzano P, Valle PD, Becchetti A, Conti M, Alberti M, et al. Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study.&#xa0; Thromb Res. 2023;223:24&#x2013;33. 10.1016/j.thromres.2023.01.015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9846886</ArticleId><ArticleId IdType="pubmed">36702064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets L, Pennington AF, Goodman AB, Rosenblum HG, Belay B, Ko JY, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021. Prev Chronic Dis. 2021;18:E66. 10.5888/pcd18.210123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8269743</ArticleId><ArticleId IdType="pubmed">34197283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Ouyang H, Fu L, Wang S, Han J, Huang K, et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol. 2020;30(8):4417&#x2013;4426. doi: 10.1007/s00330-020-06854-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00330-020-06854-1</ArticleId><ArticleId IdType="pmc">PMC7150608</ArticleId><ArticleId IdType="pubmed">32279115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JI, Burbelo PD. Reinfection with SARS-CoV-2: implications for vaccines. Clin Infect Dis. 2021;73(11):e4223&#x2013;e4228. doi: 10.1093/cid/ciaa1866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1866</ArticleId><ArticleId IdType="pmc">PMC7799323</ArticleId><ArticleId IdType="pubmed">33338197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J, Zheng Q, Madhira V, Olex AL, Anzalone AJ, Vinson A, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022;182(2):153&#x2013;162. doi: 10.1001/jamainternmed.2021.7024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.7024</ArticleId><ArticleId IdType="pmc">PMC8715386</ArticleId><ArticleId IdType="pubmed">34962505</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Cai Z, Zhang J. Insulin treatment may increase adverse outcomes in patients with COVID-19 and diabetes: a systematic review and meta-analysis. Front Endocrinol. 2021;12:696087. doi: 10.3389/fendo.2021.696087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.696087</ArticleId><ArticleId IdType="pmc">PMC8339900</ArticleId><ArticleId IdType="pubmed">34367067</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Aylor KW, Chai W, Barrett EJ, Liu Z. Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats. Am J Physiol Endocrinol Metab. 2022;322(3):E293&#x2013;E306. doi: 10.1152/ajpendo.00240.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00240.2021</ArticleId><ArticleId IdType="pmc">PMC8897003</ArticleId><ArticleId IdType="pubmed">35128961</ArticleId></ArticleIdList></Reference><Reference><Citation>Abad-Jim&#xe9;nez Z, L&#xf3;pez-Dom&#xe8;nech S, D&#xed;az-R&#xfa;a R, Iannantuoni F, G&#xf3;mez-Abril S&#xc1;, Peria&#xf1;ez-G&#xf3;mez D, et al. Systemic oxidative stress and visceral adipose tissue mediators of NLRP3 inflammasome and autophagy are reduced in obese type 2 diabetic patients treated with metformin. Antioxidants. 2020;9(9):892. doi: 10.3390/antiox9090892.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9090892</ArticleId><ArticleId IdType="pmc">PMC7555880</ArticleId><ArticleId IdType="pubmed">32967076</ArticleId></ArticleIdList></Reference><Reference><Citation>Victor VM, Rovira-Llopis S, Ba&#xf1;uls C, Diaz-Morales N, Lopez-Domenech S, Escribano-L&#xf3;pez I, et al. Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. Atherosclerosis. 2015;242(1):167&#x2013;173. doi: 10.1016/j.atherosclerosis.2015.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2015.07.017</ArticleId><ArticleId IdType="pubmed">26188541</ArticleId></ArticleIdList></Reference><Reference><Citation>Gongol B, Marin T, Peng I, Woo B, Martin M, King S, et al. AMPK&#x3b1;2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6. Proc Natl Acad Sci U S A. 2013;110(8):3161&#x2013;3166. doi: 10.1073/pnas.1222051110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222051110</ArticleId><ArticleId IdType="pmc">PMC3581905</ArticleId><ArticleId IdType="pubmed">23382195</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski M, Friebel J, Tabaraie T, Grabitz S, D&#xf6;rner A, Taghipour L, et al. Metformin is associated with reduced tissue factor procoagulant activity in patients with poorly controlled diabetes. Cardiovasc Drugs Ther. 2021;35(4):809&#x2013;813. doi: 10.1007/s10557-020-07040-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10557-020-07040-7</ArticleId><ArticleId IdType="pmc">PMC8266708</ArticleId><ArticleId IdType="pubmed">32940892</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin G, Wei Z, Ji C, Zheng H, Gu J, Ma L, et al. Metformin uniquely prevents thrombosis by inhibiting platelet activation and mtDNA release. Sci Rep. 2016;6:36222. doi: 10.1038/srep36222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36222</ArticleId><ArticleId IdType="pmc">PMC5090250</ArticleId><ArticleId IdType="pubmed">27805009</ArticleId></ArticleIdList></Reference><Reference><Citation>Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782&#x2013;792. doi: 10.1016/S2213-8587(20)30238-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(20)30238-2</ArticleId><ArticleId IdType="pmc">PMC7367664</ArticleId><ArticleId IdType="pubmed">32687793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh A, Randall MD. Does metformin affect outcomes in COVID-19 patients with new or pre-existing diabetes mellitus? A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(6):2642&#x2013;2656. doi: 10.1111/bcp.15258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15258</ArticleId><ArticleId IdType="pmc">PMC9111510</ArticleId><ArticleId IdType="pubmed">35122284</ArticleId></ArticleIdList></Reference><Reference><Citation>Parthasarathy H, Tandel D, Siddiqui AH, Harshan KH. Metformin suppresses SARS-CoV-2 in cell culture. Virus Res. 2023;323:199010. doi: 10.1016/j.virusres.2022.199010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.199010</ArticleId><ArticleId IdType="pmc">PMC9676078</ArticleId><ArticleId IdType="pubmed">36417940</ArticleId></ArticleIdList></Reference><Reference><Citation>Cory TJ, Emmons RS, Yarbro JR, Davis KL, Pence BD. Metformin suppresses monocyte immunometabolic activation by SARS-CoV-2 spike protein subunit 1. Front Immunol. 2021;12:733921. doi: 10.3389/fimmu.2021.733921.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.733921</ArticleId><ArticleId IdType="pmc">PMC8631967</ArticleId><ArticleId IdType="pubmed">34858397</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaseb E, Ghaffary S, Garjani A, Zoghi E, Maleki Dizaji N, Soltani S, et al. Long and short-term metformin consumption as a potential therapy to prevent complications of COVID-19. Adv Pharm Bull. 2023;13(3):621&#x2013;626. doi: 10.34172/apb.2023.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/apb.2023.066</ArticleId><ArticleId IdType="pmc">PMC10460805</ArticleId><ArticleId IdType="pubmed">37646067</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiernsperger N, Al-Salameh A, Cariou B, Lalau J. Protection by metformin against severe Covid-19: an in-depth mechanistic analysis. Diabetes Metab. 2022;48(4):101359. doi: 10.1016/j.diabet.2022.101359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2022.101359</ArticleId><ArticleId IdType="pmc">PMC9154087</ArticleId><ArticleId IdType="pubmed">35662580</ArticleId></ArticleIdList></Reference><Reference><Citation>Shestakova MV, Vikulova OK, Elfimova AR, Deviatkin AA, Dedov II, Mokrysheva NG. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: a nationwide retrospective cohort study of 235,248 patients in the Russian Federation. Front Endocrinol. 2022;13:909874. doi: 10.3389/fendo.2022.909874.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.909874</ArticleId><ArticleId IdType="pmc">PMC9396282</ArticleId><ArticleId IdType="pubmed">36017317</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9(5):293&#x2013;303. doi: 10.1016/S2213-8587(21)00050-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00050-4</ArticleId><ArticleId IdType="pmc">PMC8009618</ArticleId><ArticleId IdType="pubmed">33798464</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk AOY, Yip TCF, Zhang X, Kong APS, Wong VW, Ma RCW, et al. Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong. BMJ Open. 2021;11(10):e052310. doi: 10.1136/bmjopen-2021-052310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-052310</ArticleId><ArticleId IdType="pmc">PMC8529616</ArticleId><ArticleId IdType="pubmed">34670765</ArticleId></ArticleIdList></Reference><Reference><Citation>ASH Guidelines on Use of Anticoagulation in Patients with COVID-19&#x2014;Hematology.org. https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19. Accessed 28 Sep 2023.</Citation></Reference><Reference><Citation>Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, et al. American society of hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5(3):872&#x2013;888. doi: 10.1182/bloodadvances.2020003763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003763</ArticleId><ArticleId IdType="pmc">PMC7869684</ArticleId><ArticleId IdType="pubmed">33560401</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves OA, Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, Pereira-Dutra F, Mizurini DM, et al. Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way. J Mol Cell Biol. 2022;14(6):mjac039. doi: 10.1093/jmcb/mjac039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjac039</ArticleId><ArticleId IdType="pmc">PMC9492308</ArticleId><ArticleId IdType="pubmed">35759391</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianni P, Goldin M, Ngu S, Zafeiropoulos S, Geropoulos G, Giannis D. Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: a review. World J Exp Med. 2022;12(4):53&#x2013;67. doi: 10.5493/wjem.v12.i4.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.5493/wjem.v12.i4.53</ArticleId><ArticleId IdType="pmc">PMC9350720</ArticleId><ArticleId IdType="pubmed">36157337</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk FL, Kouijzer IJE, de Nooijer AH, van der Hoeven HG, Maas C, Netea MG, et al. Outcomes associated with use of a kinin B2 receptor antagonist among patients with COVID-19. JAMA Netw Open. 2020;3(8):e2017708. doi: 10.1001/jamanetworkopen.2020.17708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.17708</ArticleId><ArticleId IdType="pmc">PMC7426743</ArticleId><ArticleId IdType="pubmed">32789513</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboudounya MM, Heads RJ. COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Med Inflamm. 2021;2021:8874339. doi: 10.1155/2021/8874339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8874339</ArticleId><ArticleId IdType="pmc">PMC7811571</ArticleId><ArticleId IdType="pubmed">33505220</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontes-Dantas FL, Fernandes GG, Gutman EG, De Lima EV, Antonio LS, Hammerle MB, et al. SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. Cell Rep. 2023;42(3):112189. doi: 10.1016/j.celrep.2023.112189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112189</ArticleId><ArticleId IdType="pmc">PMC9935273</ArticleId><ArticleId IdType="pubmed">36857178</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao D, Qin Y, Liu J, Tang K, Lu S, Liu Z, et al. Orally administered BZL-sRNA-20 oligonucleotide targeting TLR4 effectively ameliorates acute lung injury in mice. Sci China Life Sci. 2023;66(7):1589&#x2013;1599. doi: 10.1007/s11427-022-2219-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-022-2219-0</ArticleId><ArticleId IdType="pmc">PMC9938506</ArticleId><ArticleId IdType="pubmed">36808291</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Liaw C, Tsai K, Chiou C, Tseng Y, Chiou W, et al. Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. Pharmacol Res. 2022;184:106424. doi: 10.1016/j.phrs.2022.106424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106424</ArticleId><ArticleId IdType="pmc">PMC9443660</ArticleId><ArticleId IdType="pubmed">36064077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadanec L, Qaradakhi T, Renee McSweeney K, Ashiana Ali B, Zulli A, Apostolopoulos V. Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment. Future Microbiol. 2021;16:205&#x2013;209. doi: 10.2217/fmb-2021-0018.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb-2021-0018</ArticleId><ArticleId IdType="pmc">PMC7885526</ArticleId><ArticleId IdType="pubmed">33569984</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JH, Lyden P. COVID-19 hypothesis: activated protein C for therapy of virus-induced pathologic thromboinflammation. Res Pract Thromb Haemost. 2020;4(4):506&#x2013;509. doi: 10.1002/rth2.12362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12362</ArticleId><ArticleId IdType="pmc">PMC7292662</ArticleId><ArticleId IdType="pubmed">32548551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali RA, Gandhi AA, Meng H, Yalavarthi S, Vreede AP, Estes SK, et al. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Nat Commun. 2019;10:1916. doi: 10.1038/s41467-019-09801-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09801-x</ArticleId><ArticleId IdType="pmc">PMC6478874</ArticleId><ArticleId IdType="pubmed">31015489</ArticleId></ArticleIdList></Reference><Reference><Citation>Okeke EB, Louttit C, Fry C, Najafabadi AH, Han K, Nemzek J, et al. Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock. Biomaterials. 2020;238:119836. doi: 10.1016/j.biomaterials.2020.119836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2020.119836</ArticleId><ArticleId IdType="pmc">PMC7075277</ArticleId><ArticleId IdType="pubmed">32045782</ArticleId></ArticleIdList></Reference><Reference><Citation>Wienkamp A, Erpenbeck L, Rossaint J. Platelets in the NETworks interweaving inflammation and thrombosis. Front Immunol. 2022;13:953129. doi: 10.3389/fimmu.2022.953129.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.953129</ArticleId><ArticleId IdType="pmc">PMC9376363</ArticleId><ArticleId IdType="pubmed">35979369</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Sig Transduct Target Ther. 2021;6(1):1&#x2013;20. doi: 10.1038/s41392-021-00679-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00679-0</ArticleId><ArticleId IdType="pmc">PMC8261820</ArticleId><ArticleId IdType="pubmed">34234112</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316&#x2013;329. doi: 10.7150/thno.49713.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.49713</ArticleId><ArticleId IdType="pmc">PMC7681075</ArticleId><ArticleId IdType="pubmed">33391477</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;384(16):1491&#x2013;1502. doi: 10.1056/NEJMoa2100433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100433</ArticleId><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepprich M, Mudry JM, Gregoriano C, Jornayvaz FR, Carballo S, Wojtusciszyn A, et al. Canakinumab in patients with COVID-19 and type 2 diabetes&#x2014;A multicentre, randomised, double-blind, placebo-controlled trial. EClinicalMedicine. 2022;53:101649. doi: 10.1016/j.eclinm.2022.101649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101649</ArticleId><ArticleId IdType="pmc">PMC9481336</ArticleId><ArticleId IdType="pubmed">36128334</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonekawa A, Shimono N. Clinical significance of COVID-19 and diabetes: in the pandemic situation of SARS-CoV-2 variants including omicron B.1.1.529. Biology. 2022;11(3):400. doi: 10.3390/biology11030400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biology11030400</ArticleId><ArticleId IdType="pmc">PMC8945151</ArticleId><ArticleId IdType="pubmed">35336774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>